LOS ANGELES, Nov. 17, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the National Cancer Institute, has joined the Company's Scientific and Medical Advisory Board. Dr. Rosenberg also is Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences, both in Washington D.C.
"We are honored to have Dr. Rosenberg serve on our Scientific and Medical Advisory Board. A leading authority on immunology and cancer, Dr. Rosenberg pioneered adoptive cell therapy using autologous tumor infiltrating lymphocytes (TILs) to successfully treat patients with metastatic melanoma," stated Anthony J. Cataldo, Chairman and Chief Executive Oficer of Genesis Biopharma. Genesis Biopharma recently licensed rights to certain intellectual property relating to the use of adoptive cell therapy using autologous TILs for the treatment of metastatic melanoma, ovarian, breast and colorectal cancers from the National Institutes of Health. "As the inventor of this therapy, Dr. Rosenberg will be an invaluable asset to Genesis Biopharma as we advance the clinical development for Contego™, our ready-to-infuse adoptive cell therapy using TILs, to treat Stage IV metastatic melanoma," added Mr. Cataldo.
Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. He has also pioneered the development of gene therapy, and was first to successfully insert foreign genes into humans and to conduct clinical studies of the gene therapy of cancer.
Dr. Rosenberg's work in tumor immunology was recently highlighted in the July issue of Oncology Times in an article titled, "Tumor-Infiltrating Lymphocytes Induce Longest Durable Regressions Ever in Metastatic Melanoma; Shows Potential of Immunotherapy to Cure." The complete article can be accessed at:
Dr. Rosenberg has been the recipient of numerous awards. He received the Meritorious Service Medal for the U.S. Public Health Service in 1981 and again in 1986, the Friedrich Sasse Prize from the University of West Berlin in 1986, the Nils Alwell Prize from Stockholm in 1987, the Distinguished Alumnus Award from The Johns Hopkins University in 1987, the Simon M. Shubitz Prize from the University of Chicago Cancer Research Center in 1988, The Griffuel Prize for Research from the French Association for Research on Cancer in 1988, and the Milken Family Foundation Cancer Award in 1988. Dr. Rosenberg twice received the Armand Hammer Cancer Prize "for pioneering work in cancer research," in 1985 and 1988. In 1991 he received the Karnofsky Prize, the highest honor given by the American Society of Clinical Oncology. In 1998 he was awarded the Ellis Island Medal of Honor. He received the John Wayne Award for Clinical Research from the Society of Clinical Oncology in 1996, the Heath Memorial Award from the MD Anderson Cancer Center in 2002, the Flance-Karl Award, the highest honor accorded by the American Surgical Association in 2002 for "innumerable contributions to the service of clinical surgery," and in 2003 he received the annual prize for scientific excellence in medicine from the American-Italian Cancer Foundation. In 2005 he received the Richard V. Smalley, M.D. Memorial Award, the highest honor given by the International Society for Biological Therapy of Cancer.
Dr. Rosenberg is a member of the American Society of Clinical Oncology, and served on its Board of directors. He is also a member of the Institute of Medicine of the National Academy of Sciences, the Society of University Surgeons, the American Surgical Association, the American Association for Cancer Research and the American Association of Immunologists. Dr. Rosenberg is the author of more than 820 articles in the scientific literature covering various aspects of cancer research, has authored eight books and is a named inventor on 189 patent and patent applications. A study published by the Institute for Scientific Information in May 1999 revealed that Dr. Rosenberg was the most-cited clinician in the world in the field of oncology for the 17 years between 1981 to 1998.
Dr. Rosenberg received his BA and M.D. degrees from The Johns Hopkins University in Baltimore, and a Ph.D. in Biophysics from Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Dr. Rosenberg became the Chief of Surgery at the National Cancer Institute, a position he has held to the present time.
About Genesis Biopharma, Inc.
Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers. The Company's lead product candidate, Contego™, is a ready-to-infuse autologous cell therapy utilizing tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma. Contego™ is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma.
For more information about the company, visit www.genesis-biopharma.com.
The foregoing announcement contains forward-looking statements that can be identified by such terminology as "expects", "hopes", "potential", "suggests", "bodes", "may", "should", "could", or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
SOURCE Genesis Biopharma, Inc.